ArticlePlants (Basel, Switzerland)2022
Bio-Fabrication of
Article in Plants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Correction: Devi et al. Bio-Fabrication ofPlants (Basel, Switzerland) · 2026Article
- Green Synthesis of Silver Nanoparticles Using Hypecoum pendulum L. Extract: In Vivo Anti-Hyperglycemic and In Vitro Antimicrobial Effects.Molecular biotechnology · 2026Article
- Biogenic Silver Nanoparticles Produced by Soil Rare Actinomycetes and Their Significant Effect onMicroorganisms · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bio-fabrication of green or plant extract-based silver nanoparticles has garnered much praise over the past decade as the methodology is environment-friendly, undemanding, non-pathogenic, and economical. In the current study, leaves of Eurale ferox (Makhana), considered as waste, were used for the bio-fabrication of silver nanoparticles (ELAgNPs). Various analytical techniques including UV−VIS spectroscopy, Field emission scanning electron microscopy equipped with an energy dispersive X-ray spectrometer (FESEM-EDX), Particle size analyzer (PSA), Fourier transform infra-red spectroscopy (FTIR) and high-resolution transmission electron microscopy (HRTEM) were used for their characterization. Their antibacterial efficacy was examined against gram positive bacterium, Bacillus subtilis and gram negative bacterium, Escherichia coli. The antioxidant potential of the ELAgNPs was compassed by 2, 2 diphenyl-1-picryl hydrazyl (DPPH; λmax = 517 nm) assay, H2O2 (λmax = 230 nm) and OH− (λmax = 520 nm)-based radical scavenging assays. The cytotoxicity was checked against the VERO cell line using 3-[4, 5-dimethyl thiazol-2-yl]-2, 5 diphenyl tetrazolium bromide (MTT) assay. A mean particle size of 26.51 ± 8.87 nm with a size distribution of 7.08−53.94 nm was obtained using HRTEM. The ELAgNPs exhibited dose-dependent antibacterial efficacy with a maximum zone of inhibition (ZOI) of 21.98 ± 0.59 mm against B. subtilis and of 16.46 ± 0.22 mm against E. coli at 500 ppm after 24 h of incubation. The median lethal concentration for the cytotoxicity analysis was found to be 9.54 ± 0.35 ppm, 120.9 ± 6.31 ppm, and 20.74 ± 0.63 ppm for ELAgNPs, commercial silver nanoparticles (CAgNPs), and silver nitrate (SN), respectively. The ordinary one-way ANOVA results exhibited a significant decrease in cell viability after 72 h of incubation at p < 0.05, α = 0.05. In conclusion, the ELAgNPs showed good antibacterial, radical scavenging and dose-dependent cytotoxicity against the VERO cells. Therefore, these could be used for biomedical applications. Phyto-constituents present in the plant not only act as reducing agents but also as stabilizing and coating agents, and the availability of a wide range of metabolites makes the green approach more promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.